Human Genome Epidemiology Literature Finder
|
Records 1 - 23 (of 23 Records) |
| Query Trace: Lymphoma and FCGR3A[original query] |
|---|
| Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002 Feb 99 (3): 754-8. Cartron Guillaume, Dacheux Laurent, Salles Gilles, Solal-Celigny Philippe, Bardos Pierre, Colombat Philippe, Watier Her |
| FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 2005 Jan 105 (1): 289-91. Lin Thomas S, Flinn Ian W, Modali Rama, Lehman Teresa A, Webb Jennifer, Waymer Sharon, Moran Mollie E, Lucas Margaret S, Farag Sherif S, Byrd John |
| FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006 Oct 108 (8): 2720-5. Kim Dong Hwan, Jung Hee Du, Kim Jong Gwang, Lee Je-Jung, Yang Deok-Hwan, Park Yeon Hee, Do Young Rok, Shin Ho Jin, Kim Min Kyoung, Hyun Myung Soo, Sohn Sang Ky |
| FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Aug 25 (24): 3712-8. Zhang Wu, Gordon Michael, Schultheis Anne M, Yang Dong Yun, Nagashima Fumio, Azuma Mizutomo, Chang Heung-Moon, Borucka Eva, Lurje Georg, Sherrod Andy E, Iqbal Syma, Groshen Susan, Lenz Heinz-Jos |
| FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. European journal of haematology 2009 Feb 82 (2): 143-7. Nishio Mitsufumi, Endo Tomoyuki, Fujimoto Katsuya, Yamamoto Satoshi, Obara Masato, Yamaguchi Keisuke, Takeda Yukari, Goto Hideki, Kasahara Ikumi, Sato Norihiro, Koike Tak |
| Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood 2010 May 115 (19): 3960-5. Stern Martin, Opelz Gerhard, Döhler Bernd, Hess Christo |
| No racial difference in allele frequencies of FCGR3A gene F158V polymorphisms in diffuse large B-cell lymphoma. European journal of haematology 2010 Nov . Hirakawa T, Yamaguchi H, Mitamura Y, Kosaka F, Dan K, Inokuchi K |
| Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Internal medicine journal 2012 Oct 42 (10): 1113-9. Keane C, Nourse J P, Crooks P, Nguyen-Van D, Mutsando H, Mollee P, Lea R A, Gandhi M |
| Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol. Pathology oncology research : POR 2012 Jan 18 (1): 43-8. Váróczy László, Zilahi Erika, Gyetvai Agnes, Kajtár Béla, Gergely Lajos, Sipka Sándor, Illés Arp |
| Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. British journal of clinical pharmacology 2012 Apr 73 (4): 597-605. Ternant David, Cartron Guillaume, Hénin Emilie, Tod Michel, Girard Pascal, Paintaud Gill |
| Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 2012 Sep 120 (13): 2650-7. Ghesquières Hervé, Cartron Guillaume, Seymour John Francis, Delfau-Larue Marie-Hélène, Offner Fritz, Soubeyran Pierre, Perrot Aurore, Brice Pauline, Bouabdallah Réda, Sonet Anne, Dupuis Jehan, Casasnovas Olivier, Catalano John Vincent, Delmer Alain, Jardin Fabrice, Verney Aurélie, Dartigues Peggy, Salles Gill |
| Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay. Cancer genetics 2013 Apr 206 (4): 130-4. Burchard Paul R, Malhotra Saurabh, Kaur Prabhjot, Tsongalis Gregory |
| FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA and cell biology 2014 Sep 33 (9): 616-23. Liu Fen, Ding Huirong, Jin Xuan, Ding Ning, Deng Lijuan, He Yan, Zhu Jun, Song Yuq |
| Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. British journal of haematology 2014 May 165 (3): 375-81. Tuscano Joseph M, Dutia Mrinal, Chee Karen, Brunson Ann, Reed-Pease Christine, Abedi Mehrdad, Welborn Jeanna, O'Donnell Robert |
| Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Oct . Kenkre Vaishalee, Hong Fangxin, Cerhan James R, Lewis Marcia, Sullivan Leslie, Williams Michael E, Gascoyne Randy D, Horning Sandra J, Kahl Br |
| The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Haematologica 2015 Apr 100 (4): 517-24. Rossi Davide, Bruscaggin Alessio, La Cava Piera, Galimberti Sara, Ciabatti Elena, Luminari Stefano, Rigacci Luigi, Tucci Alessandra, Pulsoni Alessandro, Bertoldero Giovanni, Vallisa Daniele, Rusconi Chiara, Spina Michele, Arcaini Luca, Angrilli Francesco, Stelitano Caterina, Merli Francesco, Gaidano Gianluca, Federico Massimo, Palumbo Giuseppe |
| Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. Annals of hematology 2016 Jul . Burkhardt Birgit, Yavuz Deniz, Zimmermann Martin, Schieferstein Jutta, Kabickova Edita, Attarbaschi Andishe, Lisfeld Jasmin, Reiter Alfred, Makarova Olga, Worch Jennifer, Bonn Bettina R, Damm-Welk Christi |
| The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. Annals of hematology 2016 Jul . Liu Duo, Tian Yuyang, Sun Donglin, Sun Haiming, Jin Yan, Dong M |
| FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematological oncology 2016 Jun . Ghesquières Hervé, Larrabee Beth R, Haioun Corinne, Link Brian K, Verney Aurélie, Slager Susan L, Ketterer Nicolas, Ansell Stephen M, Delarue Richard, Maurer Matthew J, Fitoussi Olivier, Habermann Thomas M, Peyrade Fréderic, Dogan Ahmet, Molina Thierry J, Novak Anne J, Tilly Hervé, Cerhan James R, Salles Gill |
| A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Annals of oncology : official journal of the European Society for Medical Oncology 2017 9 28 (11): 2806-2812. Martin P, Jung S-H, Pitcher B, Bartlett N L, Blum K A, Shea T, Hsi E D, Ruan J, Smith S E, Leonard J P, Cheson B |
| Impact of Fc?R variants on the response to alemtuzumab in multiple sclerosis. Annals of clinical and translational neurology 2019 Nov . Keller Christian W, Ruck Tobias, McHugh Donal, Pfeuffer Steffen, Gross Catharina C, Korsukewitz Catharina, Melzer Nico, Klotz Luisa, Meuth Sven G, Münz Christian, Nimmerjahn Falk, Wiendl Heinz, Lünemann Jan |
| Single-nucleotide Fc? receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood advances 2021 Aug 5 (15): 2935-2944. Strefford Jonathan C, Nowicka Malgorzata, Hargreaves Chantal E, Burton Cathy, Davies Andrew, Ganderton Rosalind, Hiddemann Wolfgang, Iriyama Chisako, Klapper Wolfram, Latham Kate V, Martelli Maurizio, Mir Farheen, Parker Helen, Potter Kathleen N, Rose-Zerilli Matthew J J, Sehn Laurie H, Trn?ný Marek, Vitolo Umberto, Bolen Christopher R, Klein Christian, Knapp Andrea, Oestergaard Mikkel Z, Cragg Mark |
| FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population. Oncoimmunology 2024 8 13 (1): 2388306. Michaël Constantinides, Nicolas Robert, Caroline Multrier, Loïs Coënon, Mauricio Campos-Mora, Carine Jacquard, Fei Gao, Sara Zemiti, Jessy Presumey, Guillaume Cartron, Jérome Moreaux, Martin Villal |
- Page last reviewed:Feb 1, 2024
- Content source: